Oxcarbazepine (Epilepsy)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8084
R24698		 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Preterm delivery (before 37 weeks of gestation) throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.86 [0.03;115.45] C
excluded (control group) 		0/4   0/7 0 4
ref
S8075
R24638		 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Preterm delivery (before 37 weeks of gestation) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 1.11 [0.04;28.53] C 0/4   2/22 2 4
ref
S10096
R36754		 Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Gestational age at birth (< 37 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 1.13 [0.58;2.19] C
excluded (control group) 		10/143   182/2,916 192 143
ref
S7808
R23126		 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Gestational age at birth (< 37 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.33 [0.70;2.54] C 10/143   91,255/1,710,441 91,265 143
ref
S8146
R25049		 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 Preterm birth (ICD-9 644.2, 774.2, 776.6, 362.20, 362.22, 362.27, 765 excluding 765.20, 765.29) early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.41 [0.83;2.40]
excluded (control group) 		-/-   -/- - -
ref
S8142
R25021		 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Preterm birth (ICD-9 644.2, 774.2, 776.6, 362.20, 362.22, 362.27, 765 excluding 765.20, 765.29) early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.33 [0.88;2.01] -/-   160,604/1,440,631 160,595 -
ref
S5927
R15100		 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 Preterm birth (<37 gestational weeks) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.94 [0.41;2.14] C
excluded (control group) 		23/527   8/173 31 527
ref
S5910
R14898		 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 Preterm birth (<37 gestational weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.00 [0.66;1.52]
excluded (control group) 		23/527   30,027/719,509 30,050 527
ref
S5918
R14994		 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Preterm birth (<37 gestational weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 0.89 [0.55;1.44] 23/527   85/1,793 108 527
ref
Total 4 studies 1.16 [0.88;1.53] 251,970 674
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Aydin, 2020 1 1.11[0.04; 28.53]241%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Coste, 2020 2 1.33[0.70; 2.54]91,26514319%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019Cohen, 2019 3 1.33[0.88; 2.01]160,595-46%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Artama (Oxcarbazepine) (Controls unexposed, sick), 2013Artama, 2013 4 0.89[0.55; 1.44]10852734%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 0% 1.16[0.88; 1.53]251,9706740.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls unexposed, NOS; 3: Oxcarbazepine) (Controls unexposed NOS; 4: Oxcarbazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.16[0.88; 1.53]251,9706740%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.33[0.94; 1.88]251,8601430%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 2 unexposed, sickunexposed, sick 0.89[0.56; 1.44]1105310%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 Tags Adjustment   - No  - No 1.33[0.71; 2.49]91,2671470%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 2   - Yes  - Yes 1.11[0.75; 1.64]160,70352735%NACohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 All studiesAll studies 1.16[0.88; 1.53]251,9706740%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 40.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.94.01.9850.000Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019Artama (Oxcarbazepine) (Controls unexposed, sick), 2013

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 5927, 5910, 8146, 8084, 10096

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.18[0.91; 1.55]281,9106700%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 3 unexposed, sick controlsunexposed, sick controls 0.89[0.56; 1.44]1105310%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.22[0.84; 1.76]2236740%NAAydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 40.510.01.0